|VENTURE FUNDING TOTAL||$24.5M|
|Series B, 1/06 |
Xytis is a biopharmaceutical company focusing on the discovery and development of innovative CNS drug candidates. The company is privately held and was created in Jan 2006 by the merger of Xytis Pharmaceuticals Ltd. (UK) and Remergent, Inc. (USA). The company received funding from Sanderling Ventures, Atlas Venture, CDC Entreprises Innovation, and Ventech. Xytis Inc. is assembling a pipeline of innovative compounds with validated mechanisms of action, addressing major unmet clinical needs in CNS fields such as Schizophrenia, Traumatic Brain Injury, Depression, Anxiety, or Insomnia. The company has two clinical stage compounds in development and operates from the USA, UK and Switzerland.